GlassScriptPhysician profile
Pedrina Salinas
NPI 1477857746
$3,985.84
in general payments reported to CMS, 2019-2025
35 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $203 · 2023: $43.62 · 2024: $1,219 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,351.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $725.22 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $365.31 | 2024-2025 | Evenity, Repatha, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.44 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $322.65 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $233.63 | 2024-2025 | |
| Antares Pharma, INC. | $209.75 | 2024-2025 | Xyosted |
| Recordati_rare_diseases_inc. | $167.00 | 2024-2025 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals LP | $141.86 | 2022-2025 | Farxiga |
| Inspire Medical Systems, INC. | $137.15 | 2021-2025 | Inspire |
| Corcept Therapeutics | $136.61 | 2024-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $124.08 | 2021 | |
| Mannkind Corporation | $121.78 | 2025 | |
| Tandem Diabetes Care, INC. | $113.40 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $97.36 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $81.80 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $79.68 | 2024-2025 | Licart, Flector, Tirosint |
| Radius Health, INC. | $73.89 | 2024-2025 | Tymlos |
| Genzyme Corporation | $72.41 | 2021 | |
| Xeris Pharmaceuticals, INC. | $60.63 | 2024-2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $49.34 | 2024-2025 | Unithroid |
| Beta Bionics, INC. | $45.71 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insulet Corporation | $25.99 | 2025 | Omnipod |
| Harmony Biosciences LLC | $24.71 | 2023 | Wakix |
| Abbott Laboratories | $22.37 | 2025 | Freestyle Libre 3 |
| Chiesi USA, INC. | $22.24 | 2025 | Mycapssa |
| Tolmar, INC. | $19.54 | 2025 | Jatenzo |
| Mylan Specialty L.P. | $18.91 | 2023 | Yupelri |
| Pfizer INC. | $18.77 | 2024 | |
| Kyowa Kirin, INC. | $18.61 | 2025 | |
| Cequr Corporation | $18.54 | 2025 | Cequr Simplicity |
| Verity Pharmaceuticals INC. | $17.92 | 2025 | Tlando |
| Sequel Med Tech, LLC | $17.20 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $15.89 | 2024 | Nexletol |
| Almatica Pharma LLC | $15.53 | 2025 | Teriparatide |
| Acella Pharmaceuticals, LLC | $13.92 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedrina Salinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.